Figure 2.
CAR T cells alter M2 macrophage phenotypes. (A) Illustration of the immune-suppression assay to evaluate M2 macrophage phenotype. (B, C) Cell surface expression of CD80 (B) and CD163 (C) in M2 macrophages in the prostate cancer immune-suppression assay evaluated by flow cytometry. Data represent two independent experiments using two different donors, in duplicate (D) Illustration of M2 macrophage stimulation with conditioned media (CM) derived from PSCA-CAR T cell:tumor cell co-cultures. (E, F) Cell surface expression of CD80 (E) and CD163 (F) in M2 macrophages evaluated by flow cytometry 48 hours after stimulating with CM collected from co-culture of DU145-PSCA tumor cells and PSCA-CAR T cells. Data represent three independent experiments using three different donors, in duplicate. (G) Transcriptional changes by bulk RNA sequencing induced in M2 macrophages on stimulation with PSCA-CAR T cell-derived CM. Expression of selected immune-related genes is shown relative to a control condition stimulated with UTD T cell-derived CM. (H) Gene ontology enrichment analysis highlighting activated immune-related biological pathways in M2 macrophages on stimulation with PSCA-CAR T cell-derived CM. CAR, chimeric antigen receptor; IL, interleukin; PSCA, prostate stem cell antigen; UTD, untransduced.